The high-speed train is chugging along. Rendering courtesy of Texas Central

The high-speed railroad from Houston to Dallas has acquired a key new player that will run day-to-day operations.

Renfe, an international railway company based in Spain, has been hired by Texas Central, the project developers, as the train's operating partner. The selection of Renfe as an operating partner marks another major step forward for the Houston-to-North Texas high-speed railroad.

Texas Central CEO Carlos Aguilar says in a statement that Renfe was chosen after a review of the best railroad operators in the world.

"Renfe has established a reputation for excellence in railroad operation in Spain and across the world, and we welcome them aboard," Aguilar says. "With their decades of expertise, they were a natural fit to join our other partners. Having the operator, the design build, and technology teams all on board and able to collaborate will ensure all aspects of the railroad are integrated and efficient."

A release calls Renfe "one of the world's most significant railways operators," running 5,000 trains daily on 7,500 miles of track. The company is integral to the transport system in its home base of Spain, handling more than 487 million passengers and 19.6 million tons of freight moved in 2017.

Renfe, in partnership with Adif, which manages Spanish railway infrastructure, will be responsible for running the trains; maintaining system components, such as engines, signals, and other equipment; and overseeing ticketing, passenger loyalty programs, and other services.

It will also provide technical advice on the design and construction of the Texas train and assist in the further development of Texas Central's operation and maintenance plans, preparing the railroad for passenger service.

Renfe is one of the biggest companies in Spain, employing nearly 14,000 people and recording revenues of 3.6 billion euros in 2017. Its high-speed systems were used by more than 36 million passengers in 2017. In March, Renfe announced that it had posted a net profit of 70 million euros in 2017, thanks in part to a jump in the number of its high-speed passengers, chalking up five consecutive years of growth.

Renfe president Isaías Táboas says the deal is a boon for Texas and for the Spanish railway industry.

"Texas Central represents a large high-speed train project in a country with high-growth potential, for which the Spanish experience will be of great help," he says. "Both Renfe Operadora and Adif have accumulated years and miles of high-speed railway development with professional teams, extensive experience, and specialized knowledge. We are committed to the success of Texas Central in improving the mobility of Texans and others in the U.S."

The agreement comes about a week after Texas Central engaged multinational firm Salini Impregilo ­– operating in the U.S. market with The Lane Construction Corporation – to lead the civil construction consortium that will build the passenger line, including viaducts, embankments, and drainage.

Spain's first high-speed line between Madrid and Seville was dedicated in 1986 and Renfe's first high-speed service connected the cities in 1992.

Its second high-speed line, from Madrid to Barcelona, was completed in 2007. Renfe also operates high-speed service from Barcelona to Paris, Lyon, and Toulouse in France. Among other major international projects, Renfe operates the recently opened high-speed train between Mecca and Medina, in Saudi Arabia.

The 200-mph train will link Houston and Dallas in 90 minutes, with a midway stop in the Brazos Valley.

The Texas train will be based on the latest generation of Central Japan Railway's Tokaido Shinkansen train system, the world's safest mass transportation system. It has operated for more than 54 years with a perfect record of zero passenger fatalities or injuries from operations, and an impeccable on-time performance record.

Texas Central and its partners are refining and updating construction planning and sequencing, guided by the Federal Railroad Administration's recently released draft environmental impact statement. The FRA now is working on a final environmental review that will help determine the project's timeline and final route.

---

This story originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston doctor wins NIH grant to test virtual reality for ICU delirium

Virtual healing

Think of it like a reverse version of The Matrix. A person wakes up in a hospital bed and gets plugged into a virtual reality game world in order to heal.

While it may sound far-fetched, Dr. Hina Faisal, a Houston Methodist critical care specialist in the Department of Surgery, was recently awarded a $242,000 grant from the National Institute of Health to test the effects of VR games on patients coming out of major surgery in the intensive care unit (ICU).

The five-year study will focus on older patients using mental stimulation techniques to reduce incidences of delirium. The award comes courtesy of the National Institute on Aging K76 Paul B. Beeson Emerging Leaders Career Development Award in Aging.

“As the population of older adults continues to grow, the need for effective, scalable interventions to prevent postoperative complications like delirium is more important than ever,” Faisal said in a news release.

ICU delirium is a serious condition that can lead to major complications and even death. Roughly 87 percent of patients who undergo major surgery involving intubation will experience some form of delirium coming out of anesthesia. Causes can range from infection to drug reactions. While many cases are mild, prolonged ICU delirium may prevent a patient from following medical advice or even cause them to hurt themselves.

Using VR games to treat delirium is a rapidly emerging and exciting branch of medicine. Studies show that VR games can help promote mental activity, memory and cognitive function. However, the full benefits are currently unknown as studies have been hampered by small patient populations.

Faisal believes that half of all ICU delirium cases are preventable through VR treatment. Currently, a general lack of knowledge and resources has been holding back the advancement of the treatment.

Hopefully, the work of Faisal in one of the busiest medical cities in the world can alleviate that problem as she spends the next half-decade plugging patients into games to aid in their healing.

Houston scientists develop breakthrough AI-driven process to design, decode genetic circuits

biotech breakthrough

Researchers at Rice University have developed an innovative process that uses artificial intelligence to better understand complex genetic circuits.

A study, published in the journal Nature, shows how the new technique, known as “Combining Long- and Short-range Sequencing to Investigate Genetic Complexity,” or CLASSIC, can generate and test millions of DNA designs at the same time, which, according to Rice.

The work was led by Rice’s Caleb Bashor, deputy director for the Rice Synthetic Biology Institute and member of the Ken Kennedy Institute. Bashor has been working with Kshitij Rai and Ronan O’Connell, co-first authors on the study, on the CLASSIC for over four years, according to a news release.

“Our work is the first demonstration that you can use AI for designing these circuits,” Bashor said in the release.

Genetic circuits program cells to perform specific functions. Finding the circuit that matches a desired function or performance "can be like looking for a needle in a haystack," Bashor explained. This work looked to find a solution to this long-standing challenge in synthetic biology.

First, the team developed a library of proof-of-concept genetic circuits. It then pooled the circuits and inserted them into human cells. Next, they used long-read and short-read DNA sequencing to create "a master map" that linked each circuit to how it performed.

The data was then used to train AI and machine learning models to analyze circuits and make accurate predictions for how untested circuits might perform.

“We end up with measurements for a lot of the possible designs but not all of them, and that is where building the (machine learning) model comes in,” O’Connell explained in the release. “We use the data to train a model that can understand this landscape and predict things we were not able to generate data on.”

Ultimately, the researchers believe the circuit characterization and AI-driven understanding can speed up synthetic biology, lead to faster development of biotechnology and potentially support more cell-based therapy breakthroughs by shedding new light on how gene circuits behave, according to Rice.

“We think AI/ML-driven design is the future of synthetic biology,” Bashor added in the release. “As we collect more data using CLASSIC, we can train more complex models to make predictions for how to design even more sophisticated and useful cellular biotechnology.”

The team at Rice also worked with Pankaj Mehta’s group in the department of physics at Boston University and Todd Treangen’s group in Rice’s computer science department. Research was supported by the National Institutes of Health, Office of Naval Research, the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, the American Heart Association, National Library of Medicine, the National Science Foundation, Rice’s Ken Kennedy Institute and the Rice Institute of Synthetic Biology.

James Collins, a biomedical engineer at MIT who helped establish synthetic biology as a field, added that CLASSIC is a new, defining milestone.

“Twenty-five years ago, those early circuits showed that we could program living cells, but they were built one at a time, each requiring months of tuning,” said Collins, who was one of the inventors of the toggle switch. “Bashor and colleagues have now delivered a transformative leap: CLASSIC brings high-throughput engineering to gene circuit design, allowing exploration of combinatorial spaces that were previously out of reach. Their platform doesn’t just accelerate the design-build-test-learn cycle; it redefines its scale, marking a new era of data-driven synthetic biology.”